BERNARDI, ANNA
BERNARDI, ANNA
Dipartimento di Chimica
Polyvalent Glycomimetic-Gold Nanoparticle Conjugates reveal effects of glycan display on Multivalent Lectin-Glycan Interactions
2024 X. Ning, D. Budhadev, S. Pollastri, I. Nehlmeier, A. Kempf, I. Manfield, B. Turnbull, S. Pöhlmann, A. Bernardi, X. Li, Y. Guo, D. Zhou
A Practical, Scalable Synthesis of 1,18‐Octadecanedioic acid‐Paclitaxel (ODDA‐PTX)
2024 V. Rositano, A. Gambini, P. Allegrini, A. Bernardi, L. Senaldi
Development of a highly selective glycomimetic ligand for L-SIGN: a new tool against SARS-CoV-2 and Ebola viruses
2023 C. Delaunay, S. Pollastri, M. Thépaut, G. Cavazzoli, L. Belvisi, C. Bouchikri, N. Labiod, A. Gimeno, A. Franconetti, J. Jiménez-Barbero, A. Ardá, R. Delgado, A. Bernardi, F. Fieschi
Powerful Avidity with a Limited Valency for Virus-Attachment Blockers on DC-SIGN: Combining Chelation and Statistical Rebinding with Structural Plasticity of the Receptor
2023 V. Porkolab, M. Lepšík, S. Ordanini, A. St John, A. Le Roy, M. Thépaut, E. Paci, C. Ebel, A. Bernardi, F. Fieschi
Scalemic natural products
2023 S. Mazzotta, V. Rositano, L. Senaldi, A. Bernardi, P. Allegrini, G. Appendino
Identification of New L-Fucosyl and L-Galactosyl Amides as Glycomimetic Ligands of TNF Lectin Domain of BC2L-C from Burkholderia cenocepacia
2023 S. Mazzotta, G. Antonini, F. Vasile, E. Gillon, J. Lundstrøm, A. Varrot, L. Belvisi, A. Bernardi
Glycomimetic antagonists of BC2L-C lectin: insights from Molecular Dynamics simulations
2023 G. Antonini, M. Civera, K. Lal, S. Mazzotta, A. Varrot, A. Bernardi, L. Belvisi
Powerful avidity with a limited valency for virus-attachment blockers on DC-SIGN: Combining chelation and statistical rebinding with structural plasticity of the receptor
2022 V. Porkolab, M. Lepšík, S. Ordanini, A. St John, A. Le Roy, M. Thépaut, E. Paci, C. Ebel, A. Bernardi, F. Fieschi
Man-based glycomimetics inhibit DC/L-SIGN interaction with SARS-CoV-2 spike protein
2022 S. Pollastri, C. Delaunay, M. Thépaut, F. Fieschi, A. Bernardi
C2-Triazole-modified mannose-based L-SIGN antagonists
2022 S. Pollastri, C. Delaunay, M. Thépaut, F. Fieschi, A. Bernardi
Targeting a Multidrug-Resistant Pathogen: First Generation Antagonists of Burkholderia cenocepacia's BC2L-C Lectin
2022 R. Bermeo, K. Lal, D. Ruggeri, D. Lanaro, S. Mazzotta, F. Vasile, A. Imberty, L. Belvisi, A. Varrot, A. Bernardi
Precision Glycodendrimers for DC-SIGN Targeting
2022 G. Goti, C. Colombo, S. Achilli, C. Vives, M. Thepaut, J. Luczkowiak, N. Labiod, R. Delgado, F. Fieschi, A. Bernardi
Rhamnose-based glycomimetic for recruitment of endogenous anti-rhamnose antibodies
2022 N. Hribernik, F. Chiodo, R.J. Pieters, A. Bernardi
Glycomimetic ligands block the interaction of SARS-CoV-2 spike protein with C-type lectin co-receptors
2022 S. Pollastri, C. Delaunay, M. Thepaut, F. Fieschi, A. Bernardi
DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist
2021 M. Thépaut, J. Luczkowiak, C. Vivès, N. Labiod, I. Bally, F. Lasala, Y. Grimoire, D. Fenel, S. Sattin, N. Thielens, G. Schoehn, A. Bernardi, R. Delgado, F. Fieschi
Structural simplification of ps-diMan based glycomimetics as DC-SIGN antagonists
2021 S. Pollastri, C. Delaunay, C. Vivès, M. Thépaut, F. Fieschi, A. Bernardi
Glycomimetics as Promising Inhibitors of Ebola Virus, Flavivirus and HIV Infections
2021 F. Fieschi, A. Bernardi, J. Rojo
One pot synthesis of thio-glycosides via aziridine opening reactions
2021 N. Hribernik, A. Tamburrini, E. Falletta, A. Bernardi
Prediction and Validation of a Druggable Site on Virulence Factor of Drug Resistant Burkholderia cenocepacia**
2021 K. Lal, R. Bermeo Malo, J. Cramer, F. Vasile, B. Ernst, A. Imberty, A. Bernardi, A. Varrot, L. Belvisi
Structure-Based Design of Glycodendrimer Antagonists for Improved DC-SIGN Targeting
2020 A. Bernardi, F. Fieschi, M. Thépaut, C. Vivès, S. Achilli, C. Colombo, G. Goti